Physician profile

Smith S Ho

Internal Medicine · Takoma Park, MD

NPI 1265611230

$2,039.85

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $363.08 2019-2020
Gilead Sciences, INC. $250.00 2019
Pfizer INC. $179.39 2019-2020
Merck Sharp & Dohme LLC $160.30 2019
Novartis Pharmaceuticals Corporation $148.91 2019-2020
Glaxosmithkline, LLC. $125.00 2019
Esperion Therapeutics, INC. $125.00 2021
Arbor Pharmaceuticals, INC. $110.97 2019-2020
Janssen Pharmaceuticals, INC $90.82 2019
Takeda Pharmaceuticals U.S.A., INC. $87.10 2019-2020
Corcept Therapeutics $80.13 2019-2020
Astrazeneca Pharmaceuticals Lp $56.72 2019-2020
Amarin Pharma, INC. $46.43 2019-2020
Kowa Pharmaceuticals America, INC. $31.48 2019
Boehringer Ingelheim Pharmaceuticals, INC. $27.73 2019
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $27.10 2019-2020
Lilly USA, LLC $20.15 2019
E.R. Squibb & Sons, L.L.C. $19.41 2020
Antares Pharma, INC. $18.49 2019
Scilex Pharmaceuticals INC. $17.16 2020
Allergan, INC. $16.31 2019
Phadia US INC. $13.75 2019
Grifols USA, LLC $12.50 2019
Sanofi Pasteur INC. $11.92 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Smith S Ho

$2,039.85

in general payments reported 2019-2025

Years
2019-2021
Top company
Novo Nordisk INC

https://glasscript.com/doctor/57542/smith-s-ho

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.